All In Biotech

Drug Trial Radar · NCT06649773

The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients

A Study to Evaluate the Efficacy and Safety of Noiiglutide Injection in Type 2 Diabetes Patients Who Received Metformin in Combination With or Without Another Oral Hypoglycemic Drug for Poor Blood Glucose Control -- a Phase III Clinical Trial of Multicenter, Randomized, Double-blind, Placebo Parallel Control

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Nov 6, 2024

Primary completion

May 28, 2025

Study completion Dec 11, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.

Conditions

  • Type 2 Diabetes

Interventions

  • Noiiglutide InjectionDrug

    Experimental group

  • Noiiglutide PlaceboDrug

    Placebo Comparator group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in glycated hemoglobin (HbA1c) relative to baseline at week 24 in SHR20004 compared to placebo.Time frame: Week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital Affiliated to Capital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.